Postoperative adjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of hepatocellular carcinoma patients with microvascular invasion: A preliminary report of a phase III, ...
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled ...
RECIST v1.1 in patients with platinum-resistant ovarian cancer (“PROC”) who progressed on a median of 7 prior lines of therapy Cytokine Release Syndrome (“CRS”) in PROC limited to Grade 1 in 11% of ...
UCI Health reviewed 31 desmoid tumor patients (2019-2025), comparing nirogacestat (n=18) with historical systemic agents including sorafenib, pazopanib, and tamoxifen/sulindac, using RECIST v1.1.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results